Research brief
Regeneron Pharmaceuticals closed the week ended 31 July at $762.6 after a 16.3% advance, its strongest week in the 52-week window. The move lifted the stock 6.9% above its weekly Trend Line and to 79.9% of its annual range, but the setup remains balanced rather than fully confirmed because the Trend backdrop is inactive, activity pressure is still negative and volume was only modestly above average.
- REGN gained 16.3% for the week and 16.6% over four weeks, compared with a -1.7% average weekly return for US Biotechnology and +0.8% for US Healthcare.
- The close at $762.6 is 6.9% above the $713.7 Trend Line, 2.0% below Sharemaestro Fair Value of $778.4 and 6.9% under the 52-week high of $818.9.
- Relative Strength improved to a positive 1.66 reading, placing REGN in the 96th percentile across 955 US Healthcare names, but activity pressure remained negative at -0.23.
- Latest volume was 5.2M shares, equal to 1.1x the 13-week average and 1.2x the 52-week average, enough to support the move but not enough to show heavy institutional participation.
- Risk remains two-sided: 13-week volatility is 5.6% versus a 52-week baseline of 4.7%, and the latest gain followed a period that included a -8.4% week in May.
A sharp rebound stands out in a mixed Healthcare week
Regeneron Pharmaceuticals delivered one of the cleaner large-cap Healthcare moves of the week, climbing 16.3% to $762.6. That was the stock’s best weekly return in the past year and placed it second in both the US Healthcare and US Biotechnology comparison groups supplied in the Sharemaestro screen. The broader sector was positive but less forceful, with US Healthcare averaging a 0.8% weekly gain, while Biotechnology was negative on average at -1.7%.
The move also improved the short-term tape: REGN is now up 16.6% over four weeks, 6.8% over 12 weeks and 37.2% over 52 weeks. The caveat is that its 12-week gain still trails the Biotechnology group’s 11.6% average, so the latest move looks more like a forceful reset from a weaker base than a fully established multi-month trend.
Price recovers the Trend Line, yet the Trend Signal is still inactive
The close at $762.6 puts REGN 6.9% above its weekly Trend Line of $713.7, a meaningful recovery after the stock sat below that level through much of July. It is also 79.9% through its 52-week range, with the latest price 6.9% below the $818.9 high and well above the $538.9 low.
Sharemaestro’s signal state remains mixed. The setup signature is a balanced read with a composite score of 57, and the Trend backdrop is inactive despite the price reclaiming territory above the Trend Line. Trend breadth across the stock’s own 52-week history is 55.8%, or 29 active weeks out of 52, which argues for improving conditions but not a persistent current regime.
Relative Strength has turned up faster than activity pressure
Relative Strength is the stronger part of the current evidence. REGN’s positive Relative Strength reading of 1.66 follows a run of deeply negative July readings and ranks the stock in the 96th percentile among 955 US Healthcare names for the week. In the Biotechnology group, where 63% of constituents show positive Relative Strength, REGN’s weekly move sat near the top alongside Corcept Therapeutics and ahead of many high-beta peers.
Market Dynamics are less convincing. Activity pressure improved to -0.23 from weaker readings earlier in July, but it remains below zero and the signal reads as no fresh buy. That divergence matters: price and Relative Strength improved sharply, while the underlying activity gauge has not yet moved into outright confirmation.
Volume supports the move, but only at baseline-plus levels
REGN traded 5.2M shares in the latest week, above the 13-week average of 4.8M and the 52-week average of 4.5M. The 1.1x 13-week volume ratio gives the rebound some participation backing, especially compared with the quieter 3.0M to 3.9M share weeks in mid-to-late July.
Still, this was not a high-conviction volume spike. The heaviest recent turnover came during weakness, including 7.7M shares in the -8.4% week of 22 May. A cleaner confirmation case would need stronger upside participation, particularly with the stock still 2.0% below Sharemaestro Fair Value and just 6.9% below its 52-week high.
Risk and watch-next framing
The opportunity evidence is clear: price is back above the Trend Line, Relative Strength has turned positive, next-week expectancy is positive at 55.64%, and the latest weekly return ranks in the strongest part of both sector and industry groups. The risk evidence is also plain: the Trend backdrop remains inactive, activity pressure is negative and the stock’s 13-week volatility of 5.6% is above its 52-week baseline of 4.7%.
The next test is whether the move can hold above the $713.7 Trend Line while activity pressure turns positive. Fair Value at $778.4 is the nearest valuation reference, followed by the $818.9 52-week high. A volume ratio above 1.5x on further strength would carry more weight than another baseline-volume advance.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/regn-biggest-week-in-year-negative-biotech-tape/.
Media and research systems can follow the RSS feed or JSON feed.